Scancell Funds a Phase 3 Melanoma Bet
Scancell agreed to acquire Nasdaq-listed Neuphoria in an all-share reverse merger and arranged up to $89 million of associated equity, debt, and acquired cash. The transaction gives Scancell a U.S. public listing and is…
